leisure time -WSS

leisure time

author：focus 2025-09-27 07:51:40 - browse：384

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： People with mental disorders often marry others with same

hotspot

WSS

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

IVF doctors demand details after CooperSurgical lawsuit

Florida health officials providing scant details on measles cases

Oral obesity drug from Viking Therapeutics hits key early target

Harvard's David Sinclair gets blowback over aging

Covid silver lining: Unprecedented look at human immune system

explore

leisure time

knowledge

Alkermes shareholders re

Insurer loopholes limit power of law against surprise medical bills

Guidelines to prevent youth baseball injuries need more muscle

Medicare Advantage 2025 payments will dip, Biden administration says

As demand for Covid shots wanes, Moderna seeks its next success

Immune cells and nerve overgrowth may explain recurring UTI pain

Psychedelics group wrestles with new pharma identity

Readout Newsletter: BridgeBio, Akero, and human embryo models

Malaria cases in Florida and Texas: Here’s what you need to know

Biden's 'march

hotspot

Lack of health data on LGBTQ+ people has serious consequences

Medicare Advantage 2025 payments will dip, Biden administration says

Republican states more likely to report Covid vaccine side effects

Medicare Advantage 2025 payments will dip, Biden administration says

Insurer loopholes limit power of law against surprise medical bills

Multiple sclerosis has subtypes with different best treatments: study

hotspot

hotspot

hotspot

hotspot